Procter & Gamble Health · NSE: PGHL · BSE: 500126
Q1 FY25 results · Apr–Jun 2024
Procter & Gamble Health reported revenue from operations of ₹283.88 crore (down 5.7% from Q1 FY24) and net profit of ₹16.78 crore (down 43.7% from Q1 FY24) for Q1 FY25 (Apr–Jun 2024), on a standalone basis.
| Item | Q1 FY25 | Q1 FY24 | YoY | Q4 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 283.88 | 301.18 | −5.7% | 252.48 | +12.4% |
| Other income | 2.13 | 5.46 | −61.0% | 2.27 | −6.2% |
| Total income | 286.01 | 306.64 | −6.7% | 254.75 | +12.3% |
| Profit before tax | 22.83 | 44.13 | −48.3% | 62.72 | −63.6% |
| Net profit for the period | 16.78 | 29.82 | −43.7% | 46.56 | −64.0% |
| EPS, basic (₹) | 10.11 | 17.96 | −43.7% | 28.00 | −63.9% |
| Net margin (%) | 5.9 | 9.9 | 18.4 |
Standalone
- Filed with BSE
- 26 Aug 2024, 10:37 IST
- Board meeting
- 21 Aug 2024
- Period
- 01 Apr 2024 to 30 Jun 2024
- Review status
- Audited
- Source
- XBRL filing on BSE